Stockreport

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]

Valneva SE - American Depositary Shares  (VALN) 
PDF the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventiv [Read more]